[Clinical consideration and management of coronavirus disease 2019]

Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):222-228. doi: 10.3760/cma.j.cn50113-20200220-00056.
[Article in Chinese]

Abstract

Coronavirus disease 2019 (COVID-19) outbreak in Wuhan city, Hubei province in December 2019 and the epidemic so rapidly happened within the whole country and abroad, raising serious problems and urgent concerns, such as: how to control most effectively human-to-human transmission? When does infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to use the existing drugs to achieve the best effect? Can available drugs effectively improve the survival rate of critical patients? In view of the above questions, this article now puts forwards the corresponding suggestions and considerations from the perspective of clinical infectious diseases physician.

2019年12月湖北武汉市暴发2019新型冠状病毒肺炎(COVID-19)疫情,并迅速发生在国内其他地区以及境外,形势岌岌可危。新发的COVID-19疫情严重且紧迫,给我们带来大量亟待解决的问题,例如:如何最有效地控制人群传播?感染人数在什么时间达到最高峰?最高峰是多少?如何做到早期诊断?有哪些新的有效抗病毒药物?如何使用现有药物达到最佳疗效?是否能有效提高危重患者救治生存率?针对以上疑问,现从感染科临床医师的角度提出相应的建议和思考。.

Keywords: 2019 novel coronavirus; COVID-19; Diagnosis; Treatment.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control*
  • Humans
  • Pandemics / prevention & control*
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control*
  • SARS-CoV-2

Substances

  • Antiviral Agents